---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-25-000136"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:10:54.574486+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pfizer Q2 2025 revenue $14.7B (+10% YoY); raises FY adjusted EPS guidance to $2.90-$3.10

## Summary
- Reported diluted EPS $0.51; adjusted diluted EPS $0.78, up 30% YoY.
- FY 2025 revenue guidance reaffirmed at $61B-$64B; adjusted EPS guidance raised by $0.10 to $2.90-$3.10.
- Vyndaqel family revenue up 21% operationally; Comirnaty +95%; Paxlovid +71%; Padcev +38%; Eliquis +6%.
- Completed $1.25B upfront in-licensing of 3SBio's SSGJ-707; one-time ~$0.20 EPS impact in Q3.
- On track for $7.2B net cost savings by end of 2027; capital allocation includes $4.9B dividends in H1.

## SEC filing metadata
- accession: 0000078003-25-000136
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800325000136/0000078003-25-000136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800325000136/pfe-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-25-000136
- JSON: https://secwatch.observer/filing/0000078003-25-000136.json
- Plain text: https://secwatch.observer/filing/0000078003-25-000136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.